Table 1.
Patient Grouping According to Clinical Characteristics and Location of the Cysts With the Stage Likely Most Influencing Their Serological Status
| Group | Patients, No. | Patients, No. (%) | ||||
|---|---|---|---|---|---|---|
| Total | No Albendazole Treatment | Albendazole <5 y Earliera | Albendazole >5 y Earlierb | Hepatic Cysts | Extrahepatic Cysts | |
| CE1 | 7 | 2 | 5 | 0 | 7 (100.0) | 0 |
| CE2 | 9 | 2 | 7 | 0 | 9 (100) | 0 |
| CE3a | 27 | 7 | 20 | 0 | 26 (96.3) | 1 (3.7) |
| CE3b | 51 | 14 | 37 | 0 | 44 (86.3) | 7 (13.7) |
| CE4 | 36 | 8 | 23 | 5 | 34 (94.4) | 2 (5.6) |
| CE5 | 18 | 12 | 2 | 4 | 16 (88.9) | 2 (11.1) |
| Postsurgical | 25 | 0 | 25 | 0 | 21 (84.0) | 4 (16.0) |
| Total | 173 | 45 | 119 | 9 | 157 (90.8) | 16 (9.2) |
a
Albendazole intake ended <5 years before collection of serum samples for this study.
b
Albendazole intake ended >5 years before collection of serum samples for this study.